Your browser does not support JavaScript or it may be disabled!
 India As It Happens
Rediff Labs will showcase innovative products that rediff is working on behind the scenes.
News   |   Images
Get Realtime News
on your webpage

About 568 results for "pfizer"

Pfizer backs out of development deal with Repligen

How did this change your view of ? More Bullish More Bearish It Didn't This impact ( ) More Bullish More Bearish Unchanged Thanks for sharing your thoughts. Submit & View Results Skip to Seeking Alpha, 2 hours ago

172 images for pfizer

Mideast Time, 1 day ago
American Banking News - Stock Ratings, 1 day ago
NDTV Profit, 2 days ago, 3 days ago
Sky News Australia, 2 days ago, 2 days ago, 2 days ago
North, 3 days ago
Fidelity Brokerage Services LLC, 3 days ago
One News Page United Kingdom, 21 hours ago
Business Recorder

Pfizer's Prevenar price cut 'inadequate,' critics say

Last week, international charity Médecins Sans Frontières called on Pfizer ($PFE) to drop its price on pneumococcal vaccine Prevenar 13. The pharma giant responded earlier this week, lopping 20 cents off the per-dose cost through vaccine alliance ...
 FierceVaccines22 hours ago Pfizer discounts pneumonia vaccine 20% for poor countries  Seeking Alpha3 days ago Pfizer cuts vaccine price for poor as GAVI group seeks $7.5 bln  CNBC3 days ago Pfizer Announces 6% Pneumococcal Vaccine Price Cut At Gavi Pledging Conference; Critics Say Reduction Not Enough  Kaiser Network.org3 days ago
Pharmaceutical Manufacturing Magazine

Pfizer (PFE) Looking To Reverse Flagging Revenue

Pfizer Inc. ( NYSE:PFE ) is exploring the market to strike a suitable deal after recent changes in its acquisition targets. The company has $33 billion in cash and intends to bring back revenue growth on a year-over-year (YoY) basis through mergers ...
 Bidness Etc1 day ago Rejected by Teva, Pfizer Keeps Shopping  Pharmaceutical Manufacturing Magazine22 hours ago Pfizer Inc. (PFE) Looks For Other Acquisition Targets After Teva Pharmaceutical (TEVA) Rejection  Bidness Etc4 days ago

Pfizer (PFE) Trading Near $33.83 Resistance Level

After closing Wednesday at $31.95, Pfizer Inc. ("PFE) presents an attractive opportunity to get a 3.75% return in just 232 days, which is an annualized return of 5.90% (for comparison purposes only).
 Individual.com1 day ago

Pfizer to hold board meeting

On 14 February 2015
 Business Standard1 day ago

Watch for Pfizer to Potentially Rebound After Falling 1.96% Yesterday

Pfizer (NYSE:PFE) traded in a range yesterday that spanned from a low of $31.51 to a high of $33.14. Yesterday, the shares fell 2.0%, which took the trading range below the 3-day low of $32.17 on volume of 27.7 million shares. Often times after ...
 Individual.com1 day ago

Pfizer struggles with patent expirations

 Fortune1 day ago
Mideast Time

Pfizer Inc. (PFE) Releases FY15 Earnings Guidance

Pfizer Inc. (NYSE:PFE) issued an update on its FY15 earnings guidance on Tuesday morning. The company provided earnings per share (EPS) guidance of $2.00-2.10 for the period, compared to the Thomson Reuters consensus estimate of $2.18, ...
 Mideast Time1 day ago Pfizer to access Prevenar 13 vaccine through Gavi alliance by 2025  PharmaBiz2 days ago Pfizer Earnings Forecast Hit By Loss Of Patents And Strengthening Dollar  Bidness Etc2 days ago Was It Foreseeable For Pfizer To Lower Its 2015 Guidance?  Benzinga.com1 day ago
NDTV Profit

Pfizer earnings slip

January 28, 2015 Pfizer reported Tuesday that revenues and profits fell again in the fourth quarter of 2014 as the drug maker continued to suffer from the loss of exclusive rights to various treatments. Revenues dropped 3.2 percent from the ...
 Business Recorder2 days ago Pfizer Q4 Profit Slips on Loss of Drug Patent Exclusivity  NDTV Profit2 days ago Pfizer earnings slip on drug patent loss  NineMSN Finance3 days ago AFP - US-pharmaceutical-earnings-Pfizer-company  Namibia Press Agency3 days ago
Pharmaceutical Technology

Pfizer agrees to pay $400m to avoid investor class action lawsuit

Pfizer has agreed to pay around $400m charge for an agreement in principle to resolve a securities class action pending against the company over off-label promotion actions. The decision was disclosed as the company released its fourth-quarter ...
 Pharmaceutical Technology2 days ago Pfizer to Pay $400M to Avoid Class Action from "Mislead" Shareholders  Pharmaceutical Manufacturing Magazine1 day ago Pfizer to pay $400mn to avert investor class action trial  Economic Times2 days ago Pfizer to pay $400 million to avert investor class action trial  CNBC2 days ago
Prev | Next
Personalize your Realtimeclose [x]
Add content to your personalized tab - My News
Add upto 6 topics of your interest:
for eg.2g Scam , World
Personalize the tabs display. ( You can add or remove the tabs )
AlertsGet updates on latest news & your favourite topics right in your inbox.Set an Alert|Manage your Alerts


Realtime News

on your Webpage

Add Widget >Get your members hooked!
Get updated on latest news & your favorite topics right in your inbox!
More     Less